Definium Therapeutics’ (DFTX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Definium Therapeutics (NASDAQ:DFTX) in a research report released on Monday morning, MarketBeat reports. The firm currently has a $70.00 price objective on the stock.

A number of other research firms have also recently weighed in on DFTX. Wall Street Zen cut shares of Definium Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Definium Therapeutics in a research report on Friday, July 17th. Robert W. Baird lifted their price target on shares of Definium Therapeutics from $57.00 to $75.00 and gave the stock an “outperform” rating in a research note on Thursday, August 13th. JonesTrading lifted their price target on shares of Definium Therapeutics from $74.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, August 13th. Finally, Bank of America assumed coverage on shares of Definium Therapeutics in a research report on Tuesday, August 18th. They issued a “buy” rating and a $75.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $64.88.

Definium Therapeutics Price Performance

Shares of NASDAQ DFTX opened at $37.85 on Monday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.95 and a current ratio of 6.95. Definium Therapeutics has a fifty-two week low of $8.77 and a fifty-two week high of $49.70. The firm has a market capitalization of $5.09 billion, a PE ratio of -11.03 and a beta of 2.23. The stock’s 50-day simple moving average is $42.62 and its 200-day simple moving average is $30.77.

Definium Therapeutics (NASDAQ:DFTX) last posted its earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.89). As a group, equities research analysts forecast that Definium Therapeutics will post -3.02 EPS for the current fiscal year.

Insider Transactions at Definium Therapeutics

In other Definium Therapeutics news, CEO Robert Barrow sold 19,023 shares of the firm’s stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $37.94, for a total transaction of $721,732.62. Following the transaction, the chief executive officer directly owned 1,494,640 shares of the company’s stock, valued at approximately $56,706,641.60. This trade represents a 1.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Matthew T. Wiley sold 2,867 shares of the stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $129,101.01. Following the sale, the insider owned 174,633 shares of the company’s stock, valued at $7,863,723.99. This trade represents a 1.62% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 67,119 shares of company stock worth $2,887,496 in the last three months. Corporate insiders own 2.40% of the company’s stock.

Institutional Trading of Definium Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in DFTX. Nykredit A S acquired a new position in shares of Definium Therapeutics in the second quarter valued at approximately $45,000. Allworth Financial LP acquired a new position in shares of Definium Therapeutics during the second quarter worth about $110,000. Integrated Wealth Concepts LLC acquired a new position in shares of Definium Therapeutics during the second quarter worth about $159,000. NewEdge Advisors LLC purchased a new position in Definium Therapeutics during the second quarter worth about $222,000. Finally, WINTON GROUP Ltd purchased a new position in Definium Therapeutics during the second quarter worth about $240,000. 27.91% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Definium Therapeutics

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Definium reported a second successful Phase 3 trial for DT120 orally disintegrating tablets in generalized anxiety disorder. The treatment produced statistically significant improvements in anxiety symptoms, supporting the company’s plans to engage with the FDA and pursue a potential 2027 regulatory filing. Definium Reports Second Phase III Success
• Positive Sentiment: Robert W. Baird raised its price target for DFTX from $75 to $79 and maintained an “outperform” rating, implying substantial potential upside from the stock’s recent trading level. Baird Raises Definium Price Target
• Positive Sentiment: HC Wainwright reiterated its “buy” rating, while Needham & Company also assigned a “buy” rating. The recommendations indicate continued Wall Street confidence in Definium’s clinical and commercial prospects. HC Wainwright Reiterates Buy Rating Needham Gives Definium a Buy Rating
• Positive Sentiment: Healthcare-focused commentary described analysts as bullish on Definium and suggested the shares could trade at a premium after the Phase 3 success, with another analysis characterizing the stock as undervalued. Analysts Are Bullish on Definium Definium Still Looks Undervalued
• Negative Sentiment: Traders purchased a large volume of DFTX put options, signaling that some market participants are positioning for downside or hedging against volatility. This is a cautionary counterpoint to the predominantly bullish analyst coverage. Large Definium Put-Option Activity

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.